Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $180,257.35 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 11,245 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $16.03, for a total transaction of $180,257.35. Following the transaction, the insider now directly owns 1,085,790 shares of the company’s stock, valued at $17,405,213.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Day One Biopharmaceuticals Stock Up 4.0 %

DAWN traded up $0.63 during midday trading on Friday, hitting $16.39. 2,315,290 shares of the company were exchanged, compared to its average volume of 954,557. The firm has a market capitalization of $1.65 billion, a P/E ratio of -15.30 and a beta of -1.51. The firm’s 50 day moving average price is $14.29 and its 200-day moving average price is $14.40. Day One Biopharmaceuticals, Inc. has a 1-year low of $10.90 and a 1-year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same period in the prior year, the company posted ($0.54) EPS. On average, sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday. JPMorgan Chase & Co. cut their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $35.71.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in DAWN. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after purchasing an additional 1,002 shares in the last quarter. Quest Partners LLC boosted its holdings in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after buying an additional 7,668 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth approximately $113,000. Point72 DIFC Ltd acquired a new position in shares of Day One Biopharmaceuticals during the 2nd quarter valued at $124,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Day One Biopharmaceuticals during the 2nd quarter valued at $163,000. 87.95% of the stock is owned by institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.